Citigroup (C) stock experienced a 1.25% drop in the latest trading session, underperforming market gains. Despite this, the company is projected to report significant year-over-year earnings and revenue growth in its upcoming disclosure, with a Zacks Rank of #2 (Buy). Investors are advised to monitor analyst estimate changes which correlate with near-term stock prices, and the stock's valuation metrics show it's currently at a discount compared to its industry average.

Ulta Beauty (ULTA) stock saw a 1.68% drop, underperforming the broader market despite gains in the S&P 500, Dow, and Nasdaq. This decline follows a 4.11% decrease over the past month, while the company prepares to release its earnings report on June 2, 2026. Analysts project earnings of $6.87 per share and revenue of $3.08 billion for the upcoming quarter, indicating year-over-year growth.

T-Mobile US, Inc. is maintaining its strategy of heavy 5G network investment combined with significant share buybacks, as confirmed by recent quarterly financial results. The company continues to show growth in postpaid accounts and its capital allocation approach, focusing on buybacks, is a key aspect for US investors. This strategy positions T-Mobile as a prominent player in the telecom sector, with performance closely tied to domestic consumer and business demand for connectivity.

The US steel industry is being propelled by infrastructure development, reshoring, manufacturing growth, and the demand from energy transition. The article highlights three key companies that are central to America's metals production. It also addresses frequently asked questions about electric arc furnace steelmaking, aluminum demand, and the effect of tariffs on domestic steel producers.

Boeing has received FAA approval to increase 737 MAX production to 47 jets per month, supported by a significant potential order from China and existing large backlog. Concurrently, its subsidiary SkyGrid is forming partnerships in Saudi Arabia and Spain to help shape future airspace management for advanced air mobility. These developments highlight Boeing's strategy to link current commercial operations with future aerospace technologies, while managing ongoing quality control and regulatory scrutiny.

ING Groep N.V. announced a new share buyback program and confirmed strong capital ratios after its Q1 2026 earnings report, with the stock trading in a tight range in Amsterdam. The bank's core business model focuses on retail and commercial banking across the eurozone and other markets, driven primarily by net interest income and fee income. The article also highlights ING's digital strategy and its relevance for US investors seeking diversification into the European banking sector.

Ecolab Inc. (NYSE: ECL) saw its stock increase by 3.3% after UBS upgraded its rating from Neutral to Buy, raising the price target to $325 from $293. This upgrade is driven by anticipated accelerated growth from datacenters, semiconductor manufacturing, and digital services, with UBS projecting annual volume growth to increase significantly. The company's strong GF Score™ of 88/100 and recent insider buying transactions further indicate its potential for long-term returns.

ORIX Corp (IX) shares dropped 3.3% to $38.61, but GuruFocus's GF Value™ indicates the stock is still 38.8% overvalued with a GF Value™ of $27.82. Despite an "Above Average" GF Score™ of 73/100 and strong momentum, the company's financial strength is rated low at 2/10, suggesting potential vulnerabilities. Investors are advised to exercise caution due to the significant overvaluation and lack of recent insider transactions.

S&P Dow Jones Indices announced changes to the S&P 500 and S&P SmallCap 600. FedEx Freight Holding Company will replace EPAM Systems Inc. in the S&P 500, while EPAM Systems will move to the S&P SmallCap 600, replacing Shutterstock Inc. Additionally, Dave Inc. will join the S&P SmallCap 600, replacing American Woodmark Corp.

Amgen Inc. remains a key player in biotechnology, with its experimental obesity drug AMG 133 keeping the company in focus within the competitive weight-loss drug market. The company also boasts a diversified portfolio of established biologics and an expanding biosimilars business. Amgen's future performance hinges on managing competitive pressures, executing clinical programs, and navigating the evolving regulatory and pricing landscape.